Factors Affecting the Response and Patient Satisfaction of Topical Immunotherapy in Alopecia Areata: A Nationwide Study
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Contact immunotherapy using diphenylcyclopropenone (DPCP) is a recommended treatment for severe alopecia areata (AA); however, few clinical factors are known, and few stan- dardized application methods affecting therapeutic efficacy have been devised. Objective: To confirm the therapeutic response of DPCP immunotherapy in AA, first we analyze the factors influencing its outcome and patient satisfaction levels, after which we standardize the DPCP treatment method for better outcomes. Methods: We utilized a nationwide questionnaire-based sur vey to assess patient satisfaction and undertook a medical record review involving 412 patients currently undergoing treatment for DPCP. Results: The patients’ mean age was 36.4 years, and 27% of the cases were diagnosed as AA in childhood. Treatment response was higher when DPCP was used to treat the entire scalp, includ- ing subclinical lesions, and longer treatment durations and longer inter vals between treatments were associated with a better treatment response. Atopy (atopic dermatitis, allergic rhinitis and bronchial asthma), thyroid disorder, and extent of hair loss were all negatively correlated with the treatment response. However, there was no correlation between the treatment response and factors such as the age of onset, a family histor y of AA, nail changes, or AA duration, which are commonly known to be associated with a poor prognosis. Conclusion: DPCP immunotherapy is an effective treatment for AA, and the study demonstrated the factors affecting DPCP treatment response and patients’ satisfaction and may contribute to standardizing the DPCP treatment method for better outcomes.
Abstract
Background: Contact immunotherapy using diphenylcyclopropenone (DPCP) is a recommended treatment for severe alopecia areata (AA); however, few clinical factors are known, and few stan- dardized application methods affecting therapeutic efficacy have been devised. Objective: To confirm the therapeutic response of DPCP immunotherapy in AA, first we analyze the factors influencing its outcome and patient satisfaction levels, after which we standardize the DPCP treatment method for better outcomes. Methods: We utilized a nationwide questionnaire-based sur vey to assess patient satisfaction and undertook a medical record review involving 412 patients currently undergoing treatment for DPCP. Results: The patients’ mean age was 36.4 years, and 27% of the cases were diagnosed as AA in childhood. Treatment response was higher when DPCP was used to treat the entire scalp, includ- ing subclinical lesions, and longer treatment durations and longer inter vals between treatments were associated with a better treatment response. Atopy (atopic dermatitis, allergic rhinitis and bronchial asthma), thyroid disorder, and extent of hair loss were all negatively correlated with the treatment response. However, there was no correlation between the treatment response and factors such as the age of onset, a family histor y of AA, nail changes, or AA duration, which are commonly known to be associated with a poor prognosis. Conclusion: DPCP immunotherapy is an effective treatment for AA, and the study demonstrated the factors affecting DPCP treatment response and patients’ satisfaction and may contribute to standardizing the DPCP treatment method for better outcomes.
참고문헌 (13)
- Mirzoyev SA, "Lifetime incidence risk of alopecia areata estimated at 2. 1% by Rochester Epidemiology Project, 1990–2009", J Invest Dermatol, 134, pp.1141~1142 (2014)
- Toussi A, "Psychosocial and psychiatric comorbidities and health-related quality of life in alopecia areata : a systematic review", J Am Acad Dermatol, 85, pp.162~175 (2021)
- Lintzeri DA, "Alopecia areata-current understanding and management", J Dtsch Dermatol Ges, 20, pp.59~90 (2022)
- Liu M, "Janus kinase inhibitors for alopecia areata : a systematic review and meta-analysis", JAMA Netw Open, 6, pp.e2320351~ (2023)
- Mahasaksiri T, "Application of topical immunotherapy in the treatment of alopecia areata : a review and update", Drug Des Devel Ther, 15, pp.1285~1298 (2021)
- Chiang KS, "Clinical efficacy of diphenylcyclopropenone in alopecia areata : retrospective data analysis of 50 patients", J Investig Dermatol Symp Proc, 17, pp.50~55 (2015)
- Olsen EA, "Alopecia areata investigational assessment guidelines--Part II", J Am Acad Dermatol, 51, pp.440~447 (2004)
- Wyrwich KW, "The Alopecia Areata Investigator Global Assessment scale : a measure for evaluating clinically meaningful success in clinical trials", Br J Dermatol, 183, pp.702~709 (2020)
- Tiwary AK, "Comparative study of efficacy and safety of topical squaric acid dibutylester and diphenylcyclopropenone for the treatment of alopecia areata", N Am J Med Sci, 8, pp.237~242 (2016)
- Singh G, "Topical immunotherapy in alopecia areata", Int J Trichology, 2, pp.36~39 (2010)
- Wasserman D, "Alopecia areata", Int J Dermatol, 46, pp.121~131 (2007)
- Rokhsar CK, "Efficacy of topical sensitizers in the treatment of alopecia areata", J Am Acad Dermatol, 39, pp.751~761 (1998)
- Huang CM, "Topical diphenylcyclopropenone in the treatment of alopecia areata : a 10-year follow-up of 86 cases in a single center", Zhonghua Pifuke Yixue Zazhi, 40, pp.214~221 (2022)